GlassScriptPhysician profile
Allison M Stiles
NPI 1013904895
$11,587.26
in general payments reported to CMS, 2019-2025
49 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,668 · 2020: $1,672 · 2021: $2,024 · 2022: $1,749 · 2023: $1,520 · 2024: $1,359 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,522.08 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,121.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $951.26 | 2019-2025 | |
| Abbvie INC. | $926.15 | 2021-2025 | Ubrelvy, Qulipta |
| Viiv Healthcare Company | $731.18 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Lilly USA, LLC | $590.00 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Theratechnologies INC. | $581.38 | 2019-2025 | Trogarzo, Egrifta |
| Glaxosmithkline, LLC. | $483.60 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $468.11 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Otsuka America Pharmaceutical, INC. | $424.27 | 2021-2025 | Rexulti |
| Pfizer INC. | $415.84 | 2019-2025 | |
| Abbott Laboratories | $408.95 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.74 | 2019-2024 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $370.53 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.91 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Stiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.